Welcome to our dedicated page for Mimedx Group news (Ticker: MDXG), a resource for investors and traders seeking the latest updates and insights on Mimedx Group stock.
MiMedx Group Inc (MDXG) delivers innovative regenerative biologics for advanced wound care and surgical recovery, leveraging human placental tissue allografts and proprietary processing technologies. This news hub provides stakeholders with verified updates about the company's operational milestones, clinical advancements, and regulatory engagements.
Investors and medical professionals will find a comprehensive repository of press releases detailing financial results, product launches, and research developments. Key coverage areas span quarterly earnings disclosures, FDA regulatory updates, strategic partnership announcements, and clinical study publications validating MDXG's biomaterial solutions.
All content is curated to maintain factual accuracy and timeliness, with direct links to official SEC filings and peer-reviewed research. The resource emphasizes MDXG's patented Purion® processing methodology and its applications in chronic wound management across healthcare settings.
Bookmark this page for streamlined access to MiMedx's latest developments in therapeutic biologics, including innovations in xenograft solutions and digital platforms enhancing clinical workflow efficiency. Regular updates ensure informed tracking of the company's progress in regenerative medicine markets.
Prescience Point Capital Management, which holds about 8.1% of MiMedx Group's shares, has nominated four director candidates for the Board at the upcoming Annual Meeting on May 27, 2021. They assert that MiMedx is undervalued, primarily due to ineffective communication regarding its Amniofix product. The firm criticizes the current Board for concentrating power and failing to represent all shareholders' interests. Prescience Point believes that effective leadership is essential for realizing the Company's potential, particularly in relation to the growth opportunities presented by Amniofix.
MiMedx Group, Inc. (Nasdaq: MDXG) has secured a Group Purchasing Agreement with Premier Inc. to supply its amniotic tissue products through the SURPASS program, effective April 1, 2021. This agreement enables SURPASS members to access special pricing on MiMedx's placental-based wound care products. CEO Timothy R. Wright emphasized the commitment to improving patient access and quality of life for those with chronic wounds. The contract establishes a specific amniotic tissue category that reinforces MiMedx's market leadership in advanced wound care, supported by robust clinical evidence.
MiMedx Group, Inc. (Nasdaq: MDXG) has appointed Phyllis Gardner, M.D., a renowned figure in academia and biotechnology, to its Board of Directors. Dr. Gardner brings over 35 years of experience in cell biology, gene therapy, and clinical research. CEO Timothy R. Wright expressed that her expertise will enhance MiMedx’s efforts in advancing its late-stage pipeline. M. Kathleen Behrens, Chair of the Board, emphasized the importance of diverse expertise in guiding the company's future. Dr. Gardner aims to leverage her knowledge to improve patient outcomes in regenerative medicine.
MiMedx Group, Inc. (Nasdaq: MDXG) reported fourth quarter net sales of $68.5 million and full-year net sales of $248.2 million for 2020, down from $299.3 million in 2019. The company faced a net loss of $49.3 million for the year, influenced by $59.5 million in investigation and restatement expenses. MiMedx anticipates a 10% increase in adjusted net sales for 2021, contingent on regulatory approvals, particularly for its biologic AmnioFix® Injectable. The company will host a conference call on March 9, 2021, to discuss these results.
MiMedx Group, Inc. (Nasdaq: MDXG) announced its participation in two upcoming virtual investor conferences. The H.C. Wainwright Global Life Sciences Conference will feature a presentation on March 10, 2021, viewable on-demand starting at 2:00 PM ET. Key management participants include Timothy R. Wright and Peter M. Carlson. The Oppenheimer 31st Annual Healthcare Conference will include a fireside chat on March 16, 2021, at 3:50 PM ET, with Wright and Robert B. Stein, M.D., Ph.D. Webcast details for both conferences are available on the company’s website.
MiMedx Group, Inc. (Nasdaq: MDXG) announced it will report its financial results for the fourth quarter and full year ended December 31, 2020, after market close on March 8, 2021. A conference call and webcast will be held on March 9, 2021, at 9:30 AM ET with key executives discussing the results. MiMedx specializes in advanced wound care and therapeutic biologics, focusing on the development of human placental tissue allografts. They have distributed over two million allografts using their proprietary PURION process.
MiMedx Group (Nasdaq: MDXG) announced that CEO Timothy R. Wright and CFO Peter M. Carlson will participate in a fireside chat at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 17, 2021, at 3:30 PM ET. A live webcast of the event will be accessible via the Company's website and the conference site. A replay will be available for 90 days post-event. MiMedx specializes in advanced wound care and therapeutic biologics, developing human placental tissue allografts using patented processes.
MiMedx Group (Nasdaq: MDXG) announces CEO Timothy R. Wright and CFO Peter M. Carlson will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13 at 4:30 PM EST. Institutional investors wishing to connect with management can contact their J.P. Morgan representatives.
Interested parties can access the live webcast on the company's website, with a replay available for 30 days post-presentation. MiMedx specializes in advanced wound care, providing over two million allografts using its proprietary PURION® process.
MARIETTA, Ga., Jan. 4, 2021 – MiMedx Group (Nasdaq: MDXG) announced that CEO Timothy R. Wright and EVP Dr. Robert Stein will participate in a fireside chat at the H.C. Wainwright BioConnect 2021 Virtual Conference from January 11-14, 2021. The chat will be pre-recorded and available on MiMedx's Investors webpage starting January 11 at 6:00 AM ET, accessible for 90 days. MiMedx is a leader in advanced wound care and therapeutic biologics, specializing in human placental tissue allografts using its proprietary PURION® process.
Prescience Point Capital Management has raised the price target for MiMedx Group Inc. (MDXG) to $31 per share. Prescience, a major shareholder with 6.5% ownership, highlights its analysis of the Amniofix injectable product currently in Phase 2b trials for knee osteoarthritis and Phase 3 for plantar fasciitis. Findings suggest Amniofix could be a revolutionary treatment, with potential for billions in annual sales. The firm anticipates FDA approval for knee OA and other indications, indicating substantial undervalue in current share prices.
FAQ
What is the current stock price of Mimedx Group (MDXG)?
What is the market cap of Mimedx Group (MDXG)?
